| __timestamp | Regeneron Pharmaceuticals, Inc. | Vericel Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 504755000 | 13774000 |
| Thursday, January 1, 2015 | 838526000 | 22479000 |
| Friday, January 1, 2016 | 1177697000 | 27388000 |
| Sunday, January 1, 2017 | 1320433000 | 35610000 |
| Monday, January 1, 2018 | 1556200000 | 49007000 |
| Tuesday, January 1, 2019 | 1834800000 | 61139000 |
| Wednesday, January 1, 2020 | 1346000000 | 68836000 |
| Friday, January 1, 2021 | 1824900000 | 97592000 |
| Saturday, January 1, 2022 | 2115900000 | 106903000 |
| Sunday, January 1, 2023 | 2631300000 | 120998000 |
| Monday, January 1, 2024 | 2954400000 |
Igniting the spark of knowledge
In the dynamic world of biotechnology, understanding financial strategies is crucial. Over the past decade, Regeneron Pharmaceuticals, Inc. and Vericel Corporation have showcased distinct approaches to their Selling, General, and Administrative (SG&A) expenses. Regeneron, a giant in the industry, has seen its SG&A expenses grow by over 400% from 2014 to 2023, reflecting its aggressive expansion and market penetration strategies. In contrast, Vericel, a smaller player, has increased its SG&A spending by approximately 780% during the same period, indicating a robust push to establish its presence. This divergence highlights the varied paths companies take in scaling operations and capturing market share. As of 2023, Regeneron's SG&A expenses are nearly 22 times that of Vericel's, underscoring the scale and scope of its operations. These insights provide a window into the strategic priorities of these biotech firms.
Selling, General, and Administrative Costs: Johnson & Johnson vs Regeneron Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing AstraZeneca PLC and Vericel Corporation
Breaking Down SG&A Expenses: Sanofi vs Regeneron Pharmaceuticals, Inc.
Comparing SG&A Expenses: Bristol-Myers Squibb Company vs Regeneron Pharmaceuticals, Inc. Trends and Insights
Selling, General, and Administrative Costs: Regeneron Pharmaceuticals, Inc. vs Insmed Incorporated
Cost Management Insights: SG&A Expenses for Regeneron Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.
Regeneron Pharmaceuticals, Inc. or Travere Therapeutics, Inc.: Who Manages SG&A Costs Better?
Comparing SG&A Expenses: Biogen Inc. vs Vericel Corporation Trends and Insights
SG&A Efficiency Analysis: Comparing Incyte Corporation and Vericel Corporation
Selling, General, and Administrative Costs: Viatris Inc. vs Vericel Corporation
SG&A Efficiency Analysis: Comparing Intra-Cellular Therapies, Inc. and Vericel Corporation
Selling, General, and Administrative Costs: MorphoSys AG vs Vericel Corporation